Vera Therapeutics, Inc. 8-K

What Happened

• On February 26, 2026, Vera Therapeutics, Inc. (VERA) issued a press release announcing its financial results for the full year ended December 31, 2025, and providing recent corporate updates. The press release is furnished as Exhibit 99.1 to the Form 8-K.
• The company states the information in this Form 8-K (including Exhibit 99.1) is furnished — not “filed” — for purposes of Section 18 of the Securities Exchange Act and is not automatically incorporated by reference into other filings. The report is signed by Chief Financial Officer Sean Grant.

Key Details

• Filing date: February 26, 2026 (Form 8-K; Item 2.02 — Results of Operations and Financial Condition).
• Reporting period covered: full year ended December 31, 2025 (financial results disclosed in the attached press release, Exhibit 99.1).
• Exhibit included: 99.1 — press release with the full-year 2025 results and corporate updates.
• Legal note: information furnished in this report is not deemed “filed” under Section 18 and has limited incorporation-by-reference effect.

Why It Matters

• This 8-K is the company’s formal disclosure that its full-year 2025 earnings, revenue and other financial metrics have been released; investors should read Exhibit 99.1 to see the specific results, cash position, and any guidance or operational updates.
• Because the release is furnished rather than filed, it carries different legal implications (limited Section 18 liability) but remains the primary source for the company’s reported financial performance and recent corporate developments.